Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

All: Soft Tissue

A Phase II Study of Pazopanib as Front-Line Therapy in Patients with Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

The purpose of this clinical research study is to learn if pazopanib is useful in treating people with soft tissue sarcoma as their first treatment.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

The purpose of this study is to Evaluate the safety, tolerability, and DLTs of AGEN1884 in advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (OER-SAR-043)

The goal of this study is to find out what effects, good and/or bad, pazopanib has on patients and their angiosarcoma.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?

The purpose of this study is to determine out if a change in diet and exercise in women with ovarian, fallopian tube, or primary peritoneal cancer, has an effect on the length of time patients are cancer-free following initial treatment.

Status: Accepting New Patients
Principal Investigator: Shohreh Shahabi

A Phase II Study of Pazopanib with Oral Topotecan in Patients with Metastatic and Non-resectable Soft Tissue and Bone Sarcomas

The purpose of this clinical research study is to learn if pazopanib when given in combination with topotecan can help to control sarcomas. The safety of this drug combination will also be studied.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing–Like Sarcomas

The purpose of this study is to compare the safety (side effects) and effectiveness of giving participants the study drug regorafenib versus a placebo (sugar pill).

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma

The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients with Advanced Soft Tissue Sarcoma

The purpose of this study is to see how an investigational drug, olaratumab, affects the way doxorubicin is handled in people with advanced soft tissue sarcoma (Sarcoma) and how safe olaratumab is when given alone and in combination with doxorubicin.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients with Soft Tissue Sarcoma

The purpose of this study is to test the safety and effectiveness of a drug called GPX-150.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Pazopanib Neoadjuvant Trial In Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)

The goal of this study is to find out what effects (good and/or bad) pazopanib given with both chemotherapy and radiation therapy has on people with intermediate and high risk non-Rhabdomyosarcoma soft tissue sarcomas (NRSTS).

Status: Accepting New Patients
Principal Investigator: David Walterhouse

A Phase II Randomized, Double Blinded Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients with Previously Treated, Unresectable Myxoid Liposarcoma

The purpose of this study is to compare the safety and effects of efatutazone (the study drug) to using a placebo (a pill that looks like the study drug but contains no medication).

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: John Kalapurakal

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

last updated: Tue - May 31, 2016 - 06:05 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.